KPRX

Kiora Pharmaceuticals Inc. (KPRX) - Q2 2025 10-Q Summary

Business Context and Reporting Period

Kiora Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company focused on developing therapies for ophthalmic diseases. This report covers the quarterly period ended June 30, 2025. The Company is classified as a smaller reporting company. As of August 6, 2025, there were 3,433,491 shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total revenue for the six months ended June 30, 2025, was $0, compared to $16.02 million in the same period in 2024. The 2024 revenue was driven by a $16 million upfront payment from the strategic development agreement with Théa Open Innovation (TOI) recognized in Q1 2024. No collaboration revenue was recognized in Q2 2025.
• Net Loss vs. Income: The Company reported a net loss of $4.35 million for the six months ended June 30, 2025, compared to net income of $11.23 million in the prior year period. This shift is primarily due to the absence of the $16 million collaboration revenue recognized in 2024.
• Operating Expenses: Total operating expenses decreased by $0.62 million year-over-year (YTD) to $4.73 million. This decrease was driven by higher collaboration and research credits ($3.65 million in 2025 vs. $1.33 million in 2024) which offset increases in gross R&D spending.
• Liquidity Position: Cash and cash equivalents decreased from $3.79 million at year-end 2024 to $1.03 million at June 30, 2025. Short-term investments decreased from $23.00 million to $19.64 million. Net cash used in operating activities was $6.51 million for the six months ended June 30, 2025.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management anticipates having sufficient cash and short-term investments ($20.67 million) to fund planned operations into late 2027. No immediate need to raise additional capital is anticipated.
• Strategic Developments:
  • Senju Agreement: In May 2025, Kiora entered an exclusive option agreement with Senju Pharmaceutical Co., Ltd. for KIO-301 in Asia. A non-refundable upfront payment of $1.25 million was received in July 2025 (subsequent event) and recorded as deferred revenue.
  • Clinical Progress: Enrollment began in Q2 2025 for the ABACUS-2 Phase 2 trial of KIO-301 (Retinitis Pigmentosa). Enrollment also began in Q2 2025 for the Phase 2 trial of KIO-104 (Retinal Inflammation).
• Risks and Contingencies:
  • Capital Needs: Future losses are anticipated. Failure to raise additional capital in the future could negatively impact operations.
  • Contingent Consideration: The Company has a liability of $4.60 million related to contingent consideration from prior acquisitions (Bayon and Panoptes), valued using Level 3 inputs. Changes in discount rates or probability of success can materially impact this liability.
  • Collaboration Dependence: A significant portion of R&D expenses for KIO-301 is reimbursed by TOI. The Company relies on these reimbursements to offset costs.

Investor Verification Checklist

• Cash Runway: Verify the $20.67 million liquidity position and the management assertion of funding operations into late 2027.
• Deferred Revenue: Confirm the treatment of the $1.25 million Senju option fee received in July 2025 and the timeline for revenue recognition.
• Reimbursement Timing: Review the "Accrued Collaboration Credit" and "Collaboration Receivables" to understand the timing of cash inflows from the TOI partnership versus expense recognition.
• Contingent Liability: Assess the sensitivity of the $4.60 million contingent consideration liability to changes in discount rates and probability of success assumptions.
• Warrant Dilution: Note the 6.99 million warrants outstanding with a weighted average exercise price of $7.37, which could impact future share count if exercised.